KACTUS

Kactus Biosystems is a pioneering biotechnology company dedicated to shaping the future of biotechnology with its bespoke protein solutions. Founded in 2018, the company specializes in designing and manufacturing high-quality and bioactive recombinant proteins for various therapeutic technologies including cell therapies, gene editing, immunotechnology, and vaccines. Kactus Biosystems stands out for its approach, where they test the configurations of proteins in different expression systems, and create 3D models to optimize protein folding, maximize bioactivity, and improve stability. The company's focus on customization and tailored solutions offers limitless potential for innovation. The latest achievement for Kactus Biosystems is the significant CNY190.00M Series B investment secured on 19 October 2022, with the backing of New Alliance Capital and Blue Bay Ventures. This investment establishes the company's position as an attractive opportunity in the biotechnology and healthcare industries. Kactus Biosystems' commitment to pushing the boundaries of biotechnology and delivering tailored solutions for transformative innovation makes it a compelling prospect for venture capital investment.